EDGE ARTICLE



View Article Online View Journal | View Issue

Check for updates

Cite this: Chem. Sci., 2023, 14, 869

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 26th July 2022 Accepted 9th December 2022

DOI: 10.1039/d2sc04166a

rsc.li/chemical-science

A unique network of attack, defence and competence on the outer membrane of the periodontitis pathogen *Tannerella forsythia*[†]

Mirosław Książek,^{‡ah} Theodoros Goulas,^{‡bc} Danuta Mizgalska,^{‡a} Arturo Rodríguez-Banqueri,^b Ulrich Eckhard, ^b ^b Florian Veillard,^a Irena Waligórska,^a Małgorzata Benedyk-Machaczka,^a Alicja M. Sochaj-Gregorczyk,^a Mariusz Madej,^a Ida B. Thøgersen,^d Jan J. Enghild,^d Anna Cuppari,^b Joan L. Arolas,^b Iñaki de Diego,^{bi} Mar López-Pelegrín,^b Irene Garcia-Ferrer,^b Tibisay Guevara,^b Vincent Dive,^e Marie-Louise Zani,^f Thierry Moreau,^g Jan Potempa^{*ah} and F. Xavier Gomis-Rüth ^b *^b

Periodontopathogenic *Tannerella forsythia* uniquely secretes six peptidases of disparate catalytic classes and families that operate as virulence factors during infection of the gums, the KLIKK-peptidases. Their coding genes are immediately downstream of novel ORFs encoding the 98–132 residue potempins (Pot) A, B1, B2, C, D and E. These are outer-membrane-anchored lipoproteins that specifically and potently inhibit the respective downstream peptidase through stable complexes that protect the outer membrane of *T. forsythia*, as shown *in vivo*. Remarkably, PotA also contributes to bacterial fitness *in vivo* and specifically inhibits matrix metallopeptidase (MMP) 12, a major defence component of oral macrophages, thus featuring a novel and highly-specific physiological MMP inhibitor. Information from 11 structures and high-confidence homology models showed that the potempins are distinct β-barrels with either a five-stranded OB-fold (PotA, PotC and PotD) or an eight-stranded up-and-down fold (PotE, PotB1 and PotB2), which are novel for peptidase inhibitors. Particular loops insert like wedges into the active-site cleft of the genetically-linked peptidases to specifically block them either *via* a new "bilobal" or the classic "standard" mechanism of inhibition. These results discover a unique, tightly-regulated proteolytic armamentarium for virulence and competence, the KLIKK-peptidase/potempin system.

"Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, Kraków 30-387, Poland. E-mail: jan. potempa@icloud.com

^bProteolysis Laboratory, Department of Structural Biology, Molecular Biology Institute of Barcelona (CSIC), Barcelona Science Park, c/Baldiri Reixac, 15-21, Barcelona 08028, Catalonia, Spain. E-mail: fxgr@ibmb.csic.es

^eDepartment of Food Science and Nutrition, School of Agricultural Sciences, University of Thessaly, Temponera str., Karditsa 43100, Greece

^dDepartment of Molecular Biology and Genetics, Aarhus University, Universitetsbyen 81, Aarhus C 8000, Denmark

^eUniversité Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), ERL CNRS 9004, Gif-sur-Yvette 91191, France

Departement de Biochimie, Université de Tours, 10 Bd. Tonellé, Tours Cedex 37032, France

⁸INRAE, Université de Tours, UMR BOA, Nouzilly 37380, France

^hDepartment of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville 40202, KY, USA

⁽Sample Environment and Characterization Group, European XFEL GmbH, Holzkoppel 4, Schenefeld 22869, Germany

† Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d2sc04166a

‡ These authors shared first authorship.

1. Introduction

Excessive, deregulated, or sustained proteolytic activity correlates with histotoxic damage, apoptosis, and chronic inflammation, which contribute to neurodegenerative and vascular diseases, organ dysfunction, tumour growth and metastasis, and periodontitis. The latter is the most prevalent inflammatory infectious disease, affecting 65 million US adults (aged >30 years), with 9% progressing to severe clinical symptoms,¹ and having detrimental effects on other systemic pathologies.² Periodontitis has an immense impact on public health and quality of life, which costs tens of billions of dollars annually.³ However, the molecular basis of periodontal pathogenesis as a microbiome-shift disease is still poorly understood.⁴

The currently accepted paradigm states that the disease is driven by dysbiotic flora, the "red complex" of oral bacteria (*Porphyromonas gingivalis*, *Treponema denticola* and *Tannerella forsythia*), which are assisted by a cohort of other periodontal pathogens.⁵ In a biofilm in the subgingival crevice, these bacteria form a tightly-knit community engaged in both competitive and cooperative interactions.⁶ Host neutrophils and macrophages cannot eradicate this community and fuel a chronic inflammatory response in the infected periodontium due to the massive release of pro-inflammatory factors and cytokines.⁷ These trigger dissolution of the periodontal ligament, alveolar bone resorption, deep periodontal pocket formation, and ultimately tooth loss in genetically susceptible individuals.⁸

Importantly, *T. forsythia* contributes directly to the pathogenicity of the dysbiotic microbial consortium by producing proteolytic enzymes as virulence factors that hinder and subvert the host-immune response.⁹ Most of these peptidases and other secreted virulence factors possess a ~9 kDa C-terminal domain¹⁰ that serves as a translocation signal for a type-IX secretion system across the outer membrane to the extracellular space.¹¹ The C-terminal domain is then removed and a lipopolysaccharide is attached to the new C-terminus, anchoring it to the outer-membrane outer leaflet.¹² The first type-IX secretion system was identified in *P. gingivalis*^{11,13,14} and others have since been found in other species of Bacteroidetes, including *T. forsythia*.^{11,15} The proteomic analysis of the *T. forsythia* outer membrane revealed at least 26 proteins with a potential C-terminal domain.¹⁶

Recently, comparative genomics has revealed that the T. forsythia genome features two exclusive loci encoding six peptidases from five disparate families according to the MER-OPS database¹⁷ (Fig. 1). One locus encodes forsilysin, a thermolysin-type M4-family metallopeptidase (MP), and miropsin-1, a trypsin-like S1D-family serine peptidase. The other encodes two metzincin-clan MPs,18 specifically mirolysin from family M43 (pappalysins;^{19,20}) and karilysin from family M10A (matrix metalloproteinases (MMPs);^{21,22}), as well as miropsin-2 (a trypsin-like S1D-family serine peptidase) and mirolase (a subtilisin-type S8A-family serine peptidase). Transcripts of all six active peptidases were detected in the gingival crevicular fluid of periodontitis sites.23 Their absence from nonpathogenic Tannerella species and any other bacteria, as well as their ability to degrade an array of host defence proteins, strongly supports a role in virulence. Indeed, three of them (karilysin, mirolysin, and mirolase) degraded the bactericidal LL-37 host peptide, induced the shedding of $TNF\alpha$ from the macrophage surface, and inactivated the host complement system.²⁴⁻²⁹ Miropsins, in turn, were strongly expressed in vivo in the subgingival dysbiotic bacterial biofilm, and the miropsin-2 transcript level correlated with the destruction of periodontal



Fig. 1 Arrangement of *T. forsythia* KLIKK-peptidase genes and upstream ORFs encoding PotA–PotE at two genomic loci. The gene distribution is based on manually curated *T. forsythia* ATCC 43037 sequences of the KLIKK-peptidase *loci* obtained by Sanger-based sequencing.²³ The sequences are available at *GenBank* under accession numbers KP715369 and KP715368. KLIKK-peptidases are named above the genes (shown as pale grey arrows) along with the family assigned in the MEROPS database (S = serine peptidase, in blue; M = metallopeptidase, in red). The corresponding potempins (PotA–PotE) are named above the ORFs (shown as black arrows). White arrows denote other putative ORFs. The *loci* are drawn to scale.

and peri-implant tissues.³⁰ All six peptidases share the presence of a prodomain, a catalytic domain, a conserved region A, a variable region B, and the type-IX secretion system C-terminal domain, whose five C-terminal residues are identical (K–L–I–K– K). Accordingly, they were collectively named KLIKKpeptidases.²³

Here, we report the unexpected finding that each of the KLIKK-peptidase genes is preceded by a short open reading frame unrelated to any protein described thus far. We investigated their function and mechanism of action by genetic, phylogenetic, biochemical, structural, functional, and *in vivo* analysis, which revealed an unprecedented network of virulence and competence regulation on the *T. forsythia* cell surface.

Results and discussion

2.1 ORFs immediately upstream of the KLIKK-peptidase genes encode unique lipoproteins (potempins)

Analysis of the flanking sequences of the unique *T. forsythia* peptidase genes based on manually curated sequences of KLIKK-peptidase *loci* of *T. forsythia* ATCC 43037 obtained by Sanger-based sequencing²³ revealed coding DNA sequences whose stop codons either overlapped with or were \leq 5 base pairs upstream of the start codons of the peptidases (Fig. S1A†). The exception was the ORF preceding the gene encoding miropsin-2, which was 876 base pairs upstream. All ORFs were co-transcribed with the linked peptidase genes (Fig. S2A and B†), and the bicistronic nature of the operon was further confirmed by the comparable expression levels of the individual ORFs and the transcripts spanning both genes (Fig. S2C†).

The DNA sequences preceding the KLIKK-peptidases encoded proteins of 118-152 residues (Fig. 1), including signal peptides of 20 residues that were predicted with high confidence (Fig. S1B[†]). To assess the distribution of these ORFs and the cognate KLIKK-peptidases, we analysed the genomes of 10 contemporary and four ancient Tannerella strains.³¹ The genes were absent from all non-pathogenic strains, suggesting they represent a disparate group of T. forsythia virulence factors. We therefore cloned all the novel ORFs preceding the KLIKKpeptidases and expressed the recombinant proteins for further analysis (Fig. S3 and Table S1[†]). We named them potempin (Pot) A, B1, B2, C, D, and E (see Fig. S4B⁺ for the UniProt database codes (UP)). Of note, we identified several other "orphan" ORFs in T. forsythia encoding putative small lipoproteins of unknown function and structure, which shared highly similar signal peptides with the potempins. One was found in an assumed operon further encompassing a thermolysin-like protease, which may recall a potempin/KLIKKpeptidase pair (BFO_0702/BFO_0703 and FJN16_03485/ FJN16_03490, in strains 92A2 and ATCC 43037, respectively). However, given the complexity of the assembly of T. forsythia genomes, which is exemplified by the misassignment of potempin and KLIKK-peptidase genes in strains ATCC 43037 and 92A2 (see Fig. S2D†), the existence of this locus needs to be experimentally verified.

Analysis of the mature sequences revealed pairwise identities among potempins of only 4–14%, with the exception of the closely-related paralogues PotB1 and PotB2, which showed 82% identity (Fig. S1B†). Sequence-based phylogenetic analysis suggested that PotA might be more closely related to PotD, followed by PotE, whereas PotC clustered weakly with PotB1 and PotB2 (Fig. S4A†). Remarkably, the signal peptides showed 65% identity, even though they are cleaved following secretion and do not affect the mature protein structure or function (Fig. S4B†). Contrary to expectations, the signal peptides of PotA and PotE, as well as those of PotC and PotD, were even identical, whereas those of the closely related PotB paralogues were the most divergent. This contrasts with the 19/20-residue signal peptides of the cognate KLIKK-peptidases, which were divergent except for a few highly-conserved residues (Fig. S4C†). The evolutionary implications of these observations are discussed later (see Section 2.12).

2.2 Potempins specifically inhibit their genetically-linked peptidases

In rare cases, the activity of bacterial peptidases is controlled by co-transcribed protein inhibitors,³² such as *Staphylococcus* sp. staphopains by staphostatins,³³ *Streptococcus pyogenes* streptopain by its endogenous inhibitor,³⁴ and serralysin MPs from *Erwinia, Pseudomonas*, and *Serratia* spp. by endogenous serralysin inhibitors.^{35,36} We thus tested the ability of the potempins to inhibit recombinant KLIKK-peptidases (karilysin, mirolase, mirolysin, and forsilysin) *in vitro*. We found that each potempin

inhibited its co-transcribed peptidase but not the others. The stoichiometry of inhibition was close to 1 in all cases (Fig. 2A) and the formation of stoichiometric inhibitor:peptidase complexes was confirmed by size-exclusion chromatography and gel electrophoresis (Fig. S5A and B⁺). Exceptionally, the PotE: forsilysin complex (stoichiometry of inhibition = 1.55 \pm 0.06) contained a fraction of truncated inhibitor (cleaved at A¹¹⁵-I¹¹⁶, potempin residue numbering in superscript according to the corresponding UP, see Fig. S4B[†]), explaining the slightly higher stoichiometry of inhibition. In all cases, peptidase inhibition by the co-transcribed potempin followed a Michaelis-Menten kinetics (Fig. 2B) and was consistent with reversible competitive inhibition (Fig. 2C). All derived K_i values were in the nanomolar range (2-10 nM), which indicates potent inhibition (Fig. 2B). There was not enough functional miropsin-1 or miropsin-2 available to determine the inhibition kinetics, but we qualitatively observed that miropsin-1 was inhibited by PotB1—in a concentration dependent manner—but not PotB2 (Fig. S6[†]).

We investigated the specificity of the inhibitors in more detail by testing a cohort of other peptidases. PotA did not inhibit *Staphylococcus aureus* aureolysin (M4 family), *Serratia* sp. serralysin (M10B) or protealysin (M4), or *Pseudomonas aeruginosa* LasB (*alias* pseudolysin; M4) or aeruginolysin (M10B). Similarly, PotB1 and PotB2 did not inhibit S1-family serine peptidases (bovine trypsin, bovine chymotrypsin, porcine



Fig. 2 Potempins efficiently inhibit their co-transcribed KLIKK-peptidases. (A) Stoichiometry of inhibition (SI) values of potempins PotA–PotD in the presence of karilysin, mirolase, mirolysin and forsilysin, respectively, indicate 1:1 complexes. Peptidases were incubated with increasing amounts of inhibitor for 15 min, and the residual enzymatic activity was measured and plotted against the inhibitor:peptidase molar ratio. Enzymatic activity in the absence of inhibitor was taken as 100%. Data are means \pm SD (n = 3). (B) Velocities of reaction (V) for the same complexes were determined for different concentrations of fluorescence-conjugated casein (FTC-casein) and plotted against the substrate concentration at various inhibitor concentrations. The derived K_i values are means \pm SD (n = 3). (C) Double reciprocal plots of V against substrate at various inhibitor concentrations showed that inhibition is reversible and competitive.

pancreatic elastase, human neutrophil elastase or human cathepsin G). Among S8-type serine peptidases, PotC inhibited Bacillus licheniformis subtilisin Carlsberg as a reversible competitive inhibitor with an apparent K_i of 82 nM (Fig. S7A and B[†]) but with a stoichiometry of inhibition of 6 (Fig. S7C[†]). The formation of the inhibitory complex was confirmed by sizeexclusion chromatography (Fig. S7D and E⁺), but it was unstable and PotC was cleaved within the complex, so the inhibition efficiency was much lower than against mirolase (Fig. S7F and G⁺). Other serine peptidases, including the physiologically-relevant S8-family members Fusobacterium nucleatum fusolisin, Treponema denticola dentilisin, and Streptococcus gordonii challisin, as well as the aforementioned S1family serine peptidases, were unaffected by PotC. PotD was inactive against Methanosarcina acetivorans ulilysin (M43 family) and PotE did not inhibit the M4-family MPs thermolysin from Bacillus thermoproteolyticus, aureolysin and LasB, even at a 25-fold molar excess. Taken together, these data suggest that potempins evolved as regulators to specifically and potently inhibit their genetically-linked KLIKK-peptidases.

2.3 PotA is a novel specific inhibitor of MMP-12

The MMP family is part of the metzincin clan of MPs and is responsible for many physiological and pathological functions in mammals, with 23 paralogues in humans.²¹ The four tissue inhibitors of metalloproteinases (TIMPs; MEROPS family I35) are the only endogenous protein inhibitors, and they broadly inhibit MMPs.³⁷ The karilysin catalytic domain includes all the characteristic MMP features and is currently the only structurally and functionally characterized member of this family outside mammals.^{22,38} We therefore tested the ability of PotA to inhibit a comprehensive cohort of mammalian MMPs (Table S2†). The activity of full-length MMPs 1, 2, 3, 7, 9 and 14 was unaffected, and that of full-length MMPs 8, 10 and 13, as well as the catalytic domain of MMP-20, was only slightly impaired ($K_i > 100$ mM). In contrast, human and murine MMP-12 (full-length and isolated catalytic domains) were strongly inhibited by PotA ($K_i = 5$ –10 nM). PotA is therefore a novel, potent, and highly-specific inhibitor of MMP-12. Whereas TIMPs are 22–29 kDa proteins with N-terminal and C-terminal domains responsible for broad-spectrum MMP inhibition and protein binding functions, respectively,³⁹ PotA features a single compact 98-residue domain that fulfils the inhibitory function (Section 2.9).

2.4 Potempins and their co-transcribed peptidases form stable complexes

The neutralisation of potentially damaging proteolytic activity requires the formation of stable inhibitor:peptidase complexes. Accordingly, we incubated preformed PotA:karilysin, PotC:mirolase, PotD:mirolysin and PotE:forsilysin complexes at different temperatures and assessed the integrity of the inhibitors over time by SDS-PAGE (Fig. 3A). After 24 h, intact PotA, PotC and PotD were recovered from their complexes, regardless of the incubation temperature. Furthermore, the residual activity increased only slightly – although significantly – from 1% in the control to 2–4% in samples incubated at 20 °C or 37 °C (Fig. 3B). In contrast, the PotE:forsilysin complex released the



Fig. 3 Stability of the inhibitory complexes and resistance of potempins to proteolysis. Inhibitory complexes of the potempins and their target peptidases at the stoichiometry of inhibition shown in Fig. 2 were incubated at different temperatures for 24 h. (A) The integrity of the complex components was evaluated by SDS-PAGE. (B) The residual peptidase activity released from the complex was determined with Azocoll as the substrate. As a control, we determined the residual activity of the complex incubated for 15 min at room temperature ("control"). (C) PotA, PotC or PotD (80 μ M) were incubated with bovine trypsin and chymotrypsin (chym), neutrophil elastase (NE), *P. gingivalis* cysteine peptidase Tpr or gingipains (Kgp and RgpB) at a 100 : 1 molar ratio at 37 °C for 8 h to determine their resistance to proteolysis. The samples were then analysed by SDS-PAGE. (D) The residual inhibitory activity of PotA, PotB and PotC pre-incubated with non-target peptidases was determined by measuring their inhibitory potency against the targeted KLIKK-peptidases karilysin, mirolase and mirolysin, respectively, with Azocoll as the substrate. The activity of KLIKK-peptidases incubated alone was taken as 100%. Data are means \pm SD (n = 3).

aforementioned truncated form of the inhibitor under all conditions we tested. There was generally no further degradation of the inhibitor and no significant activity was detected, although the incubation at 37 °C was an exception. This is reminiscent of the specific insect metallopeptidase inhibitor (IMPI) from *Galleria mellonella*, which strongly inhibits selected thermolysins despite being cleaved at its inhibitory loop.⁴⁰

Next, we investigated the stability of the potempins against proteolytic degradation by incubation with non-target peptidases and subsequent assessment of their capacity to inhibit their cognate KLIKK-peptidases. PotA, PotC and PotD were insensitive to cysteine peptidases secreted by P. gingivalis (Tpr and gingipains), which co-occur with T. forsythia in the subgingival biofilm, and human neutrophil elastase, which is abundant in inflammatory exudates (Fig. 3C). This resistance to proteolytic inactivation by non-targeted proteases is consistent with the competence of the potempins to control the activity of KLIKK-peptidases in the highly proteolytic environment of periodontal pockets. PotD and PotC were inactivated by the exogenous peptidase chymotrypsin, which caused $\sim 90\%$ and \sim 50% loss in inhibitory activity against mirolysin and mirolase, respectively, while PotA was resistant (Fig. 3D). Notably, inactivation correlated with a small decrease in the molecular mass of PotD (Fig. 3C), which suggests cleavage of the C-terminally located inhibitory segment.

2.5 Potempins are outer-membrane-anchored lipoproteins

All six potempins featured a variant of the lipobox motif [LVI] [ASTVI][GAS]C at the end of the signal peptide (Fig. S4B⁺), which is a characteristic of bacterial lipoproteins.⁴¹ The conserved cysteine becomes the new N-terminal residue of the mature protein and undergoes lipid modification for membrane anchorage.42 Consistently, some potempins, including PotA, were identified in the proteome of the outer membrane¹⁶ and the outer-membrane vesicles of T. forsythia.43 However, the exact subcellular localisation (inner-membrane outer leaflet, outermembrane inner leaflet or outer-membrane outer leaflet) cannot be predicted with confidence.44 Therefore, we used antibodies against PotA to detect it in T. forsythia membrane fractions enriched for the outer membrane. We used TfsA and TfsB as outer-membrane markers. These highly-glycosylated proteins (200 and 210 kDa) are secreted by the type-IX secretion system¹⁵ and are unique to the semicrystalline S-layer on the surface of *T. forsythia* (Fig. 4A).⁴⁵ As shown in Fig. 4B and C, PotA was mainly located in the outer-membrane fraction, with the small amount in the inner-membrane fraction probably reflecting contamination with outer-membrane material during sample preparation (supported by the presence of small amounts of TfsA and TfsB). The association of PotA with the outer-membrane was confirmed by its detection in outermembrane vesicles (Fig. 4D) in a dot-blot analysis in which



Fig. 4 Potempins are located on the *T. forsythia* cell surface. (A) Transmission electron microscopy images of a blebbing (outer membrane vesicle forming) *T. forsythia* ATCC 43037 cell. CM = (inner) cell membrane, OM = outer membrane, S = S-layer composed of TfsA and TfsB glycoproteins (adapted from ref. 107 with permission). (B) Comparison of PotA distribution in *T. forsythia* fractions derived from whole culture (WC), washed cells (C), cell-free culture medium (M), outer-membrane vesicles (OMV), soluble proteins derived from cytoplasm and periplasm (C/P), and cell envelope (CE). (C) Detection of PotA in cell envelope (CE), outer (OM) and inner (IM) membranes by western blotting (top panel) and visualisation of TfsA/TsfB by protein staining (bottom panel). (D) Dot-blot analysis of intact wild-type *T. forsythia* (WT-*Tf*) and *potA*^{null} cells (upper row) and cells lysed by sonication (lower row) to detect PotA (left panel) and a biotinylated IM protein (right panel). Dotted circles indicate sites where dots were placed on the nitrocellulose. (E) Inhibition of karilysin, mirolase, and mirolysin proteolytic activity against Azocoll as the substrate by intact, washed *T. forsythia* cells (red bars) and OMV (black bars). The activity of the isolated peptidases (green bars) was taken as 100%. Data are means \pm SD (n = 3). (F) Inhibition of karilysin proteolytic activity against Azocoll as the substrate by OMV produced by wild-type *T. forsythia* (WT-*Tf*) and the *potA*^{null} strain. The activity of the peptidase alone was taken as 100% and the amount of OMV was standardized based on protein concentration determined by the BCA assay. Data are means \pm SD (n = 3). (G) Flow cytometry analysis showing the surface exposure of PotA in *T. forsythia* wild-type cells (WT-*Tf*) (left panel) and in the *potA*^{null} mutant strain (right panel) using anti-PotA antibodies.

intact cells and lysed cells produced equivalent signals when probed with anti-PotA antibodies. In this assay, a biotinylated inner-membrane *T. forsythia* protein, as well as a PotA-deficient mutant strain (*potA*^{null}), were used as controls (Fig. 4D). Moreover, using the FACS approach, we unambiguously verified the surface location of PotA (Fig. 4G). Accordingly, the proteolytic activity of karilysin, mirolase and mirolysin was inhibited by washed, intact *T. forsythia* cells and outer-membrane vesicles (Fig. 4E), which further confirms the cell-surface location of PotA and the other potempins. Finally, only wild-type *T. forsythia* but not the *potA*^{null} mutant inhibited karilysin in a concentration-depended manner (Fig. 4F). Given the small size of the potempins compared with TsfA/TfsB, the former must be intercalated between the latter close to the outermembrane surface, either intercalated or beneath the S-layer.

2.6 PotA protects surface proteins from degradation by karilysin but does not contribute to prokarilysin secretion and maturation

The surface location of the potempins may protect *T. forsythia* surface proteins such as TsfA/TsfB and BspA from KLIKK-peptidases. Of note, BspA is an important virulence factor of *T. forsythia*,⁴⁶ which should not be hindered by endogenous proteins. To assess this hypothesis, we compared the SDS-PAGE protein band profile and the content of BspA in the cell envelope and outer-membrane vesicles of wild-type *T. forsythia* with that of the *potA*^{null} mutant strain. Although the protein pattern of the cell envelope and outer-membrane vesicles was similar in both strains (Fig. 5A), western blotting analysis revealed a significantly fainter immunoreactive band for BspA in both



Fig. 5 PotA protects the outer membrane against karilysin without affecting the maturation of the latter and further contributes to *T. forsythia* competence *in vivo*. (A) Analysis of proteins in the cell envelope (CE) and outer-membrane vesicles (OMV) of wild-type *T. forsythia* (WT-*Tf*) and the karilysin-null (Δkly) and *potA*^{null} strains by SDS-PAGE and (B) western blotting using rabbit antisera against BspA. Protein amounts were normalized based on total protein concentration determined by the BCA assay. Detection of karilysin in washed cells (C) and particle-free culture medium (D) of wild-type *T. forsythia* and *potA*^{null} strains by western blotting. The Δkly strain was used as a control for the specificity of the anti-karilysin IgGs used. (E) Dot-blot analysis of the wild-type *T. forsythia* and *potA*^{null} outer-membrane vesicles and intact cells. Dotted circles indicate sites where dots were placed on the nitrocellulose. The results shown are representative of 2–3 independent biological replicates (see also Fig. S8†). (F) Wild-type *T. forsythia* (WT) and strains lacking PotA (*potA*^{null}) or karilysin (Δkly) were inoculated into medium and the OD₆₀₀ was recorded as a proxy of bacterial growth. Data are means \pm SD (n = 2 technical replicates) and are representative of three independent (*potA*^{null} or Δkly) strains of *T. forsythia*. Aliquots of the chamber contents were withdrawn immediately after inoculation, after 12 h and after 24 h, and then serially diluted and plated on agar in triplicate. After 8 days, the colony-forming-unit count was determined. Data are means \pm SD (n = 6; one-way ANOVA, **** = p < 0.0001).

fractions of the mutant strain (Fig. 5B and S8†). This finding underpins that PotA protects BspA from degradation.

Edge Article

We next analysed the effect of PotA on the maturation of karilysin. Notably, KLIKK-peptidases are secreted as latent zymogens, which are autocatalytically activated.^{27,29,38,47–49} Western blotting of washed *T. forsythia* cells revealed the presence of full-length prokarilysin (55 kDa) and a partially processed form (48 kDa) as major immunoreactive bands, while only minor amounts of mature karilysin (18 kDa) were detected (Fig. 5C). Only mature karilysin was found in the culture medium (Fig. 5D). In all cases, karilysin was detected regardless of the presence of PotA. These results underpin that karilysin is processed and released to the extracellular environment in a PotA-independent manner.

We further assessed the presence of karilysin in outermembrane vesicles and on the bacterial cell surface by dotblot analysis using the wild type and the *potA*^{null} strain, which lacks PotA activity but expresses karilysin normally (Fig. 5C). Karilysin was detected only in intact cells and outer-membrane vesicles of the wild type but not the mutant strain (Fig. 5E). Apparently, outer-membrane vesicles are scavenging mature karilysin secreted into culture medium by forming stable inhibitory complexes, which are also present on the *T. forsythia* cell surface. Cumulatively, these results confirm that PotA – and most likely the other protempins – protect the surface of *T. forsythia* against the endogenous KLIKK-peptidases, which are secreted *via* the type-IX secretion system and released into the environment as mature enzymes.

2.7 PotA contributes to T. forsythia competence in vivo

Given the high selectivity of the potempins and the importance of protecting the bacterial cell surface from endogenous virulence factors (see Section 2.6), we investigated the biological function of PotA by means of the *potA*^{null} strain. Initially, this strain grew comparably to the wild type and a strain mutant for karilysin (Δkly) in rich medium *in vitro* (Fig. 5F). However, after 2-4 days *potA*^{null} accumulated less biomass than the wild type and Δkly , which we attribute to the unrestrained activity of karilysin on endogenous surface proteins compromising the integrity of the outer membrane. Next, we compared strain vitality using a murine model of subcutaneous chambers, in which bacteria are challenged by the host immune system (Fig. 5G). We found that the *potA*^{null} strain was severely compromised in vivo. Together with the data presented in Sections 2.2 and 2.5, this suggests that PotA (and by extrapolation the other potempins) protects the outer membrane against the endogenously secreted KLIKK-peptidases, thus providing an important element of competence. This is reminiscent of the T. forsythia serpin-type inhibitor miropin, which blocks the virulence cysteine peptidases Kgp and Tpr secreted by red-complex partner P. gingivalis and protects against the host peptidases neutrophil elastase, cathepsin G and plasmin.50-52 In the particular case of PotA, this protection probably extends to MMP-12, which is a major defence component secreted by host macrophages,53,54 thus also contributing indirectly to bacterial competence via a secondary route.

2.8 Potempins feature two types of β-barrel scaffolds

To investigate the molecular determinants of potempin functionality, we obtained structural data from seven experimental crystal structures and four high-confidence comparative models (Tables S3 and S4†). This revealed that potempins are antiparallel β -barrels with hydrophobic cores traversing the structures top to bottom. Three proteins (PotA, PotC and PotD; Fig. 6B–D) adopt a five-stranded (β 1– β 5) Greek-key oligonucleotide/ oligosaccharide-binding fold (OB-fold⁵⁵), whereas the rest (PotE and the PotB proteins; Fig. 6G–I) are eight-stranded (β 1– β 8) up-and-down class-IV β -hairpin-repeat barrels.⁵⁶ Inspection of their coulombic surfaces reveals an overall homogeneous distribution of charges, with no conspicuous charged patches (Fig. S4D†). This is consistent with these inhibitors interacting with their peptidase targets mainly through selected surface loops (see Section 2.9).

The superposition of PotA, PotC and PotD (Fig. 6A and Table S5[†]) revealed that their central β -barrel scaffolds are cylinders with an inner diameter of \sim 12 Å, which coincide for the five constituent *β*-strands, both in orientation and connectivity (Fig. 6E). The smallest potempin (PotA, 98 residue) adopts the minimal β -barrel structure (Fig. 6B). The loops (L) connecting strands β^2 and β^3 (L $\beta^2\beta^3$) and L $\beta^4\beta^5$ feature "loop I" (A⁶⁰–D⁶⁴) and "loop II" (I⁹⁸–G¹⁰³), respectively, which protrude ${\sim}12$ Å from the barrel surface and are engaged in target inhibition, in particular via Y⁶³ and D⁶⁴ (Section 2.9). PotC (132 residues) includes a large segment encompassing a "reactive-centre loop" (RCL; $F^{116}-I^{129}$), which is grafted between $\alpha 2$ and $\beta 5$ and runs in a near extended conformation for E¹²⁰-M¹²⁶ (Fig. 6C). It projects \sim 20 Å from the barrel and is linked *via* a disulfide bond (C⁴²-C¹²⁴) to a subjacent "scaffold loop" (T³⁹-A⁴⁶), which provides overall rigidity to the RCL around a "reactive-site bond" (ref. 57; M¹²⁶-N¹²⁷) that is essential for peptidase inhibition (Section 2.10). A curved β -ribbon ($\beta 2'\beta 2''$) inserted after $\beta 2$ sticks out from the bottom lateral barrel surface and is folded back to support the scaffold loop. Finally, PotD (105 residues) also contains a RCL $(K^{106}-V^{114})$ extending ~20 Å away from the barrel surface (Fig. 6D), with K¹¹⁰ playing a major functional role (Section 2.11). Moreover, β-hairpin β1β2 ("loop A") projects \sim 13 Å from the surface of the barrel and may act as an ancillary inhibitory element. Finally, an unpaired cysteine $(C^{31}; Fig. 6D)$ gave rise to covalent dimers in the crystal structure of PotD, but these were deemed functionally irrelevant. Remarkably, all main functional loops in the OB-fold potempins - the RCL in PotC and PotD, and loop II in PotA - are inserted between strands β 4 and β 5 and project away from the bottom lateral barrel surface (Fig. 6B-D).

Among the β -hairpin-repeat-barrel potempins (Fig. 6F and Table S5†), PotE (107 residues) contains a RCL (D¹¹²–L¹¹⁹) that is inserted between β 7 and β 8 and is centred on I¹¹⁶ for inhibition (Fig. 6G and Section 2.11). Moreover, L β 1 β 1' ("loop α ") may play an ancillary role in peptidase binding. Finally, we obtained two high-confidence computational models of PotB1 and PotB2 using *AlphaFold*,⁵⁸ which predicted they are also eight-stranded barrels (Fig. 6H and I). The superposition of PotE, PotB1 and PotB2 revealed that this subfamily has the



Fig. 6 Potempin structures. (A) Topology of the five-stranded ($\beta1-\beta5$) Greek-key oligonucleotide/oligosaccharide binding (OB)-fold featuring the cylindrical β -barrels that scaffold the experimental structures of PotA (B), PotC (C) and PotD (D). All strands are antiparallel except edge-strands $\beta1$ and $\beta5$, and they adopt a clockwise swirl, which results in the strands being rotated $\sim40^{\circ}$ with respect to the barrel axis. Panels (B)–(D) show ribbon-type plots in two orthogonal views, parallel to (top) and down the barrel axis (bottom). (E) Superposition of the C α traces of PotA (gold), PotC (green) and PotD (cyan) in cross-eye stereo in broadside (left) and end-on (right) views with respect to the barrel axis. (F) Topology of the antiparallel eight-stranded ($\beta1-\beta8$) up-and-down class-IV β -hairpin-repeat barrel shaped as a conical frustum that is found in the experimental structure of PotE (G) and the predicted structures of PotB1 (H) and PotB2 (I), which are shown in the two orthogonal orientations of

shape of a conical frustum with top and bottom diameters of ${\sim}15$ Å and ${\sim}20$ Å, respectively (Fig. 6F and J). The β -strands of all the structures coincide in orientation and connectivity.

2.9 PotA is a novel bilobal inhibitor of karilysin and MMP-12

We solved the structures of PotA in complexes with human MMP-12 and T. forsythia karilysin (Table S3⁺). The inhibitor inserts like a wedge into the active-site clefts of both MMPs through small interfaces (390 Å², $\Delta^{i}G = -4.6$ kcal mol⁻¹ and 370 $Å^2$, $\Delta^i G = -4.7$ kcal mol⁻¹, respectively), so that loops I and II occupy primed $(S_1'-S_3')$ and non-primed (S_2-S_5) sub-sites of the cleft (sub-site nomenclature in bold, see ref. 59 and 60) through N⁶¹-Y⁶³ and T⁹⁹-A¹⁰², respectively (Fig. 7A-C). These residues bind the cleft is a similar manner to a true MMP substrate, except that loop-I residues bind in the reverse direction. Specifically, A^{102} occupies S_2 and Y^{63} penetrates the S_1 ' specificity pocket, which, depending on the MMP paralogue, can accommodate medium-to-large hydrophobic side chains.61 PotA selectively and potently inhibited MMP-12 only across mammalian MMPs (Section 2.3 and Table S2[†]) because this orthologue has a very deep, tube-like S_1' pocket that traverses the entire molecule62 and easily allows room for the side chain of Y^{63} . Remarkably, the S_1 sub-site of the cleft is free, which explains why the inhibitor is not cleaved. In addition, the carboxylate of D⁶⁴ provides a strong warhead that binds and thus blocks the catalytic zinc, and further contacts the general base/acid glutamate of MMP-12 (E_{219} ; peptidase numbering in subscript, here according to UP P39900; Fig. 7C) or karilysin (E₁₅₆; for UP, see Fig. S4C[†]). Superposition of the MMP-12 and karilysin complexes revealed near identical binding except for a small relative rotation of the MMP moieties of $\sim 9^{\circ}$ (Fig. 7B). Comparison of unbound and complexed PotA revealed that significant rearrangement occurs in loop I to allow optimal accommodation to the MMP active-site clefts by enabling zinc binding through D^{64} and rotation of Y^{63} to penetrate the S_1 pockets.

Overall, PotA inhibits MMPs using a "bilobal mechanism" (Fig. 7A and C), which is distantly reminiscent of the "raised elephant trunk mechanism" described for the specific inhibition of astacin MPs by fetuin-B^{63,64} and contains elements of the "aspartate-switch mechanism" of latency found in certain MP zymogens.⁶⁵ Finally, an OB-fold β-barrel scaffold has also been found in the otherwise unrelated structures of TIMPs.^{37,39} However, TIMPs use their N-terminal domain to bind the catalytic zinc of MMPs *via* the N-terminal α-amino group and only block the primed side of the cleft.

2.10 PotC is a new standard-mechanism inhibitor of subtilases

We also solved the structure of PotC in a complex with *T. forsythia* mirolase, a peptidase herein reported for its structure

for the first time (ESI Results and Fig. S9†). Briefly, mirolase contains a 348-residue subtilisin-type S8-family catalytic domain centred on a catalytic serine-peptidase triad comprising D_{231} , H_{283} and S_{477} . Despite its broad substrate specificity similar to other subtilisins²⁷ (Section 2.2), the structure of mirolase differs substantially from that of the archetypal *Bacillus* subtilisin in the loops conforming the active-site cleft. The *Tannerella* enzyme contains 25% more residues and four new calcium-binding sites (Fig. S9 and Table S6†). In particular, mirolase contains a "protruding hairpin" projecting ~30 Å from the surface (Fig. S9†) rather than the classic "upper-rim segment" framing the top of the non-primed side of the cleft as found in subtilases. This hairpin is supported by "backing loop 1" and "backing loop 2".

In the complex, PotC inserts like a shim into the active-site cleft of mirolase (Fig. 7D and E) and uses a substantially larger interface than PotA (1327 Å², $\Delta^{i}G = -17.1 \text{ kcal mol}^{-1}$). Its RCL is pinched between the protruding hairpin and backing loop 2 in front, and by loop $L\beta7\beta8$ and the lower rim of the cleft behind. The RCL interacts with this lower rim $(S_{361}-Y_{364})$ in an extended, antiparallel, substrate-like conformation (see ESI Results[†] for details on the mirolase structure and Fig. S9[†]) between I^{123} in S_4 and N^{127} in S_1' (Fig. 7E), and further contacts calcium site 1 within backing loop 2. The RCL flanks the reactive-site bond (M¹²⁶-N¹²⁷), with the side chain of M¹²⁶ nestling into the S_1 specificity pocket of the enzyme (Fig. 7E). The overall architecture and geometry of the complex conforms to the "standard-mechanism" widely described for serinepeptidase inhibitors^{66,67} and for a few MP inhibitors⁴⁰ but here applying to an inhibitor with an uncharacterized fold. These inhibitors bind to target enzymes in a substrate-like manner, adopting an extended, "canonical" conformation. The reactivesite bond of the RCL is cleaved very slowly due to the high stability of the Michaelis complex, yielding very low dissociation rate constants.68 The complex can therefore dissociate to produce either the intact or cleaved forms of the inhibitor. Indeed, the high resolution of the PotC:mirolase crystal structure (1.1 Å; see Table S3[†]) revealed that the complex corresponds to a cleavage-reaction intermediate in which the catalytic nucleophile $S_{477}O\gamma$ is very close (2.55 Å) to the scissile carbonyl carbon and perpendicular to the plane of the carbonyl group (Fig. 7F). This distance exceeds the length of a covalent C-O bond but is shorter than the sum of the van der Waals radii, so that it represents an intermediate of the nucleophilic addition preceding the tetrahedral intermediate. Moreover, the scissile carbonyl oxygen was stabilised by oxyanion-hole atoms N₃₉₉Nδ2 and S₄₇₇N (ESI Results†).

Finally, the orientation of the inhibitor β -barrel with respect to the peptidase is similar in the PotA and PotC complexes: the barrel axis is roughly perpendicular to the peptidase active-site cleft (compare left panels of Fig. 7A and D).

⁽B)–(D) (top and bottom). The first four strands are rotated ~20° with respect to the barrel axis, the second four by ~60°. (J) Same as (E) for PotE (orange), PorB1 (white) and PotB2 (grey). In the distinct panels, regular secondary-structure elements are depicted as arrows (β -strands) or ribbons (α -helices) and are labelled, as are the N/C-termini. Regions engaged in peptidase inhibition are shown in magenta. Important functional residues are depicted for their side chain and are labelled. Disulfide bonds appear as green sticks, and an unpaired cysteine in (D) as red sticks is indicated by a red arrow. RCL = reactive-centre loop.



Fig. 7 Structures of PotA and PotC complexes with peptidases. (A) Ribbon-type plot of PotA (in gold; loops I and II in purple) in a complex with the catalytic domain of human MMP-12 (in light blue) in two orientations (left and right). In the left panel, the peptidase is shown in the traditional "standard orientation",⁶⁰ in which the active site-cleft is viewed broadside running from left (non-primed side) to right (primed side), followed by $a \sim 60^{\circ}$ rotation around the *x*-axis. The catalytic zinc of the peptidase is shown as a magenta sphere coordinated by three histidine residues (H₂₁₈, H₂₂₂, and H₂₂₈; light blue sticks). The structural zinc (in magenta) and the three calcium cations (green spheres) are also displayed, as is the general base/acid glutamate (E₂₁₉). The two most relevant residues of PotA engaged in inhibition, Y⁶³ and D⁶⁴, are highlighted as pink sticks. (B) Superposition of the C α -traces of the PotA:MMP-12 (gold/light blue) and PotA:karilysin (red/purple) complexes in the orientation of (A, right). (C)

2.11 PotD and PotE are probably standard-mechanism inhibitors of MPs

We obtained a high confidence docking model of the PotD:mirolysin complex based on the experimental structures of PotD (this work) and a mirolysin product complex.⁴⁸ We also calculated a reliable computational model of the PotE:forsilysin complex based on the experimental structure of PotE (this work), a high-confidence computational model of forsilysin, and the complex between the M4-peptidase thermolysin and IMPI.⁴⁰

In the PotD:mirolysin complex (Fig. 8A), the RCL would insert in a substrate-like manner into the active site of the enzyme and interact with the cleft's upper-rim segment, here formed by strand $\beta7$ (D₁₇₉-Q₁₈₅; see ref. 48 for structural details of mirolysin), in an antiparallel manner between W^{108} and D^{112} (Fig. 8B). This inhibition would conform to the standard mechanism, which for MPs has been described at the structural level only for IMPI.^{40,69} Most relevantly, the side chain of K¹¹⁰, which flanks the reactive-site bond, would intrude into the S_1 specificity pocket, thus matching the preference of the enzyme for basic residues,²⁹ and would form a salt bridge with D₂₈₉ at the pocket bottom. In addition, D₁₇₀ would bind R¹¹¹, and the side chains of I^{109} and W^{108} would occupy the S_1 and S_2 sub-sites by interacting with M_{147} plus L_{180} and F_{186} plus F_{188} , respectively. Atom Y₂₈₆On would bind the reactive-site bond carbonyl. The shape of PotD further suggests that, farther on the primed side of the cleft, the tip of loop A $(R^{55}-R^{56})$ may contact loop L β 8 α 4 of the MP, which protrudes from the surface and shapes the outermost cleft region,⁴⁸ possibly through a salt bridge (R⁵⁵-E₂₁₃). Loop A is kept in a competent conformation for interaction by an ionic network involving the RCL (D⁵⁸-R⁵⁶-D¹¹²; Fig. 8B).

Like PotD, PotE would insert its RCL to interact with the upper-rim strand of the forsilysin cleft ($D_{317}-N_{322}$) *via* segment I¹¹⁴–I¹¹⁶ (Fig. 8C). The side chain of residue I¹¹⁶, which flanks the reactive-site bond (A¹¹⁵–I¹¹⁶), would penetrate the S₁' pocket, thus matching the general specificity of thermolysin-type MPs for middle-sized hydrophobic side chains (Fig. 8D). As found in the IMPI:thermolysin complex⁴⁰ and our *in vitro* inhibition studies (Section 2.2), PotE is cleaved at A¹¹⁵–I¹¹⁶ during complex formation while retaining its inhibitory capacity. Moreover, R¹¹⁷ in S₂' might form a salt-bridge with D₃₃₆ of the MP. Finally, and likewise reminiscent of PotD, the tip of a β-ribbon adjacent to the RCL (here loop α) might assist in binding of the primed side of the cleft *via* interactions involving S⁴⁶ and R⁴⁹.

Taken together, as for the OB-fold barrels PotA and PotC, the β -hairpin-repeat-barrels PotD and PotE would also display a similar orientation relative to the peptidase in the corresponding complexes, here with the barrel axis roughly parallel to the active-site cleft (compare left panels of Fig. 8A and C).

2.12 Corollary

To thrive in the harsh ecological niche of the gingival crevice, periodontopathogenic T. forsythia has uniquely evolved six colocalized and co-transcribed peptidases and specific inhibitors, the KLIKK-peptidase/potempin system. The secreted peptidases (representing five families and two chemical classes) act as soluble virulence factors targeting the host and bacterial competitors for resources in the extracellular environment. The inhibitors, which are inserted close to the outer-membrane surface beneath the S-layer and in outer-membrane vesicles, contribute to bacterial competence and fitness in vivo by protecting surface proteins from proteolysis before the peptidases are released to the extracellular space. Notably, although potempins solely use the regular secretory pathway and remain anchored on the outer leaflet of the outer membrane, their target peptidases are soluble and use the latter pathway plus a Cterminal domain-mediated type-IX secretion system for export to the extracellular space.

Given their disparate signal peptides, as often found in unrelated proteins,⁷⁰ KLIKK-peptidases appear to have been acquired gradually over long evolutionary timescales, possibly by horizontal gene transfer from mammalian hosts or other bacteria in the oral or gut microbiomes.^{27,38} In contrast, potempins appear to have arisen from a small number of events close in time to regulate the co-transcribed KLIKK-peptidases.

Structurally, potempins adopt two β -barrel architectures that are new for peptidase inhibitors and inhibit their target peptidases either through a bilobal mechanism or the standard mechanism, using surface loops in two distinct orientations of their β -barrel axes relative to the active-site clefts. Most potempins potently and selectively inhibit only their cotranscribed KLIKK-peptidase by forming a firm complex. Exceptionally, PotA also strongly inhibits MMP-12, but not other MMPs. MMP-12 is almost exclusively expressed in macrophages, which trigger the primary line of defence and the inflammatory response to invading periodontopathogens, including *T. forsythia*.^{71,72} Moreover, MMP-12 participates in bacterial clearance when challenged with Gram-positive bacteria,⁵³ and it is secreted to the extracellular space.⁵⁴ Thus,

Close up of a similar view as shown in (A, left) in stereo, focusing on the interaction between PotA and MMP-12 in the cleft. Relevant peptidase and inhibitor residues are shown as sticks and are numbered in blue and red, respectively. (D) Ribbon-plot of PotC (in green; RCL in blue) in a complex with the catalytic domain of mirolase (in plum) in two orientations (left and right). In the left panel, the peptidase is shown in a similar orientation with respect to its active-site cleft as in (A, left). The protruding hairpin and the backing loop 2 of the peptidase are shown as white ribbons and are labelled. The lower rim and loop L β 7 β 8 from mirolase are shown as yellow ribbons and are labelled. The catalytic triad (D₂₃₁, H₂₈₃ and S₄₇₇) is shown as red sticks, and the M¹²⁶ side chain of PotC as cyan sticks. (E) Close up of a similar view as shown in (D, left) in stereo, displaying the side chains of the RCL residues of PotC and the three catalytic residues of the peptidase as sticks. The RCL is anchored to the subjacent scaffold loop *via* the disulfide C⁴²–C¹²⁴. Residue numbers are in blue and red for the peptidase and the inhibitor, respectively. (F) Detail of the mirolase active site showing the catalytic triad with magenta carbons and black labels and PotC segment V¹²²–Q¹²⁸ (selected residues are numbered in red). The final ($2mF_{obs}$ – DF_{calc})-type Fourier map at 1.10 Å resolution is shown as a semi-transparent green surface contoured at 1.5 σ above threshold for the depicted residues only. The hydrogen bonds of the catalytic triad (S₄₇₇O_Y–H₂₈₃N_E2 and H₂₈₃N\delta1–D₂₃₁O\delta2) are shown as yellow lines and are labelled with the corresponding distance in Å, as is the interaction between S₄₇₇O_Y and the scissile carbonyl carbon, M¹²⁶C.



Fig. 8 Models of PotD and PotE complexes with peptidases. (A) Ribbon-plot of PotD (in cyar; RCL and loop A in plum) in the modelled complex with the catalytic domain of mirolysin (in tan) in two orientations (left and right). In the left panel, the peptidase is shown in a similar orientation with respect to its active-site cleft as MMP-12 in Fig. 7A. The catalytic zinc of the peptidase is shown as a magenta sphere coordinated by three histidine residues (H_{224} , H_{228} and H_{234} ; brown sticks). The two calcium cations (green spheres) are also displayed, as are the general base/acid glutamate (E_{225}) and E_{213} . The most relevant residue of PotD potentially engaged in inhibition (K^{110}), as well as ancillary R^{55} , are further displayed as pink sticks. (B) Close up of a similar view as shown in (A, left) in stereo, focusing on the predicted interaction between PotD and mirolysin in the active-site cleft. Relevant residues of the peptidase and inhibitor are shown as sticks and are numbered in blue and red, respectively. (C) Ribbon-plot of PotE (in orange; RCL and loop α in blue) in the modelled complex with the forsilyin catalytic domain model (in light green) in two orientations (left and right). In the left panel, the peptidase is shown in a similar orientation with respect to its active-site cleft as MMP-12 in Fig. 7A. The catalytic zinc of the peptidase is shown as a magenta sphere coordinated by three residues (H_{348} , H_{352} and E_{372} ; green sticks). A predicted calcium cation (red sphere) is also displayed, as is the general base/acid glutamate (E_{349}). The most relevant residues of PotE potentially engaged in inhibition (I^{116} from the RCL and R^{49} from loop α) are displayed as cyan sticks. (D) Close up of a similar view as shown in (A, left) in stereo, focusing on the predicted interaction between PotE and forsilysin in the active-site cleft. Relevant residues of the peptidase and inhibitor are shown as sticks and are numbered in blue and red, respecti

PotA offers a strategy to escape the human host response and adds up to the cognate broad-spectrum TIMPs as a novel, specific, and physiologically relevant MMP inhibitor that may be suitable for the treatment of MMP-12-mediated diseases.

3. Experimental procedures

3.1 Reagents

Human neutrophil elastase, cathepsin G, and α_2 -macroglobulin were purchased from Athens Research and Technology. Succinyl-A-A-P-F-pNA, batimastat, ecotin, subtilisin Carlsberg, bovine pancreatic trypsin, porcine pancreatic elastase, B. thermoproteolyticus thermolysin, and bovine pancreatic a-chymotrypsin were from Sigma-Aldrich. Serratia sp. serralysin and protealysin, P. aeruginosa LasB and aeruginolysin, F. nucleatum fusolisin, T. denticola dentilysin, and S. gordonii challisin were commercially expressed and purified by Creative Enzymes. Azocoll was from EMD-Millipore, fluorescein-labelled casein (FTC-casein), the PageRuler pre-stained protein ladder (10-180 kDa), restriction endonucleases BamHI and XhoI, and Phusion DNA polymerase were from Thermo Fisher Scientific. The expression vector pGEX-6P-1, glutathione-Sepharose 4 fast flow resin, and 3C (PreScission) protease were from Cytiva. Fulllength human MMPs 1, 2, 3, 7, 8, 9, 10, 12, 13, 14, and fulllength murine MMP-12 were purchased from R&D Systems Europe. The catalytic domain of human MMP-20 was from Enzo Fischer Scientific. Primers (Table S1[†]) were synthesized by Genomed. All other chemical reagents, unless stated otherwise, were from BioShop Canada.

3.2 Recombinant peptidase production, purification, and titration

P. gingivalis gingipains (Kgp and RgpB) and Tpr peptidase, *S. aureus* aureolysin, *M. acetivorans* ulilysin, KLIKK-peptidases (mirolase, karilysin, mirolysin, forsilysin, miropsin-1 and miropsin-2), and the catalytic domains of human and murine MMP-12 were produced and/or purified as previously described.^{23,27,29,47,69,73,74} Peptidases were active-site titrated with α_2 -macroglobulin (mirolase, mirolysin, forsilysin and subtilisin Carlsberg), ecotin (chymotrypsin, trypsin, elastase and cathepsin G) or batimastat (karilysin).

3.3 Cloning, expression, and purification of recombinant potempins

With the exception of *potD*, the sequences encoding the potempins, without the predicted signal peptides and with the N-terminal cysteine (C^{21}) replaced with alanine, were directly amplified by PCR from genomic DNA extracted from *T. forsythia* ATCC 43037 using the primers listed in Table S1.[†] The *potD* gene was amplified by nested PCR. Next, vector pGEX-6P-1 and the PCR products were digested with BamHI/NotI (*potA*, *potB1*, *potB2*, *potC* and *potE*) or EcoRI/NotI (*potD*) and ligated. *Escherichia coli* strain DH5 α was transformed with the recombinant plasmids, and positive clones were selected. The integrity of the genetic constructs, including an N-terminal glutathione-S-transferase-tag for purification and a PreScission peptidase

cleavage site for tag removal, was confirmed by DNA sequencing. Expression plasmids were introduced into E. coli strain BL21 (DE3) (EMD-Millipore), and the bacteria were grown in lysogeny broth (Lennox) containing 100 µg mL⁻¹ ampicillin at 37 °C to an OD₆₀₀ of 0.75–1 and then cooled down to 20 °C. Recombinant fusion protein expression was induced with 0.1 mM isopropyl-1- β -D-thiogalactopyranoside. After 16 h at 20 ° C, the cells were collected by centrifugation ($6000 \times g$, 10 min, 4 ° C), resuspended in phosphate-buffered saline supplemented with 0.02% sodium azide, and lysed by sonication (one cycle of 30×0.5 s pulses at 70% power output per pellet from 1 L culture) using a Branson digital 450 sonifier (Branson Ultrasonics). Cell lysates were clarified by centrifugation (50 000 $\times g$, 50 min, 4 °C) and loaded onto a 5 mL column with preequilibrated glutathione-Sepharose 4 fast-flow matrix at 4 °C. The glutathione-S-transferase-tag was removed by in-column cleavage with PreScission protease, which left five or eight (only for PotE) vector-derived additional residues (G-P-L-G-S or G-P-L-G-S-P-E-F) at the N-terminus of the recombinant potempins. The eluted proteins were concentrated to 2 mL and size-exclusion chromatography was carried out at a flow rate of 1.5 mL min⁻¹ on a HiLoad 16/600 Superdex 75 pg column (Cytiva) connected to an ÄKTA Pure FPLC system (Cytiva), and previously equilibrated with 5 mM Tris·HCl, 50 mM sodium chloride, 0.02% sodium azide, pH 8.0. Protein concentrations were determined by averaging the values obtained with the BCA Protein Assay Kit (Thermo Fisher Scientific) and those resulting from measuring A280 with a NanoDrop device (Thermo Fisher Scientific) applying the theoretical extinction coefficient calculated with ProtParam (http://web.expasy.org).

3.4 Inhibition assays

Karilysin, mirolysin, mirolase, subtilisin Carlsberg, chymotrypsin, trypsin or elastase (200 nM), as well as miropsin-1 or forsilysin (2 µM), were pre-incubated for 15 min at 37 °C in assay buffer (50 mM Tris·HCl, 150 mM sodium chloride, 2.5 mM calcium chloride, 0.02% sodium azide, pH 7.6), alone or in the presence of a 10-fold molar excess of the corresponding potempin. The residual peptidase activity was determined using 200 μ L Azocoll (15 mg mL⁻¹ suspension) as a substrate according to the manufacturer's instructions. All other peptidases were incubated with a 10-fold weight excess of the corresponding potempin and the residual activity was determined with Azocoll. With respect to the inhibition by intact cells and outer-membrane vesicles, karilysin, mirolysin and mirolase (at 1 nM) were incubated with fractions for 15 min at 37 °C in assay buffer (50 µL), and 200 µL of Azocoll substrate suspension (15 mg mL^{-1}) was added.

3.5 Stoichiometry of inhibition

Mirolase, mirolysin, karilysin (all at 200 nM) or subtilisin (50 nM) were mixed with increasing concentrations of Pot C, PotD, PotA or PotC, respectively, in 50 μ L reactions to yield enzyme:inhibitor molar ratios of 0–9. After pre-incubation for 30 min at 37 °C, residual peptidase activity was determined using Azocoll as the substrate.

3.6 Determination of inhibition modes and inhibition constants

Karilysin (10 nM), mirolase (15 nM), mirolysin (7.5 nM), subtilisin (0.5 nM) or forsilysin (15 nM) were incubated at 37 °C in microtiter plates containing 100 µL assay buffer per well, in the presence of increasing amounts of PotA (0-8 nM), PotC (0-18.75 nM), PotD (0-9 nM for mirolysin and 0-192 nM for subtilisin) or PotE (0-20 nM), respectively. After incubation for 15 min at 37 °C, we added 100 μ L FTC-casein (0–120 μ g mL⁻¹) and residual proteolytic activity was recorded ($\lambda_{exc} = 485$ nm; $\lambda_{\rm em} = 538$ nm) for 30 min using a SpectraMax Gemini XPS microplate reader (Molecular Devices). The modes of inhibition of the target peptidases were determined graphically with a Lineweaver-Burk plot constructed using eqn (1):

$$\frac{1}{V} = \frac{K_{\rm m}}{V_{\rm max}} \times \frac{1}{[S]} + \frac{1}{V_{\rm max}} \tag{1}$$

where V is the reaction velocity, V_{max} is the maximum reaction velocity, $K_{\rm m}$ is the Michaelis–Menten constant, and [S] is the substrate concentration. The apparent inhibition constant K_i was derived using GraphPad Prism, with eqn (2) for competitive inhibition:

$$V = V_{\max} \times \frac{[S]}{K_{\mathrm{m}}^{\mathrm{obs}} + [S]}; \quad K_{\mathrm{m}}^{\mathrm{obs}} = K_{\mathrm{m}} \times \left(1 + \frac{[I]}{K_{\mathrm{i}}}\right) \tag{2}$$

where $K_{\rm m}^{\rm obs}$ is the Michaelis–Menten constant in the presence of inhibitor and [I] is the inhibitor concentration.

3.7 Assessment of complex formation by size-exclusion chromatography

Mixtures of karilysin and PotA (at molar ratios of 1:1 and 1:5), mirolase and PotC (1: 0.75 and 1: 1.5), subtilisin and PotC (1: 4 and 1:6), mirolysin and PotD (1:0.75 and 1:1.5), and forsilysin and PotE (ratios 1:0.8 and 1:1.6) were pre-incubated for 15 min at 20 °C in buffer (5 mM Tris·HCl, 50 mM sodium chloride, 2.5 mM calcium chloride, 0.02% sodium azide, pH 7.6). Each reaction mixture contained 75 µg peptidase and inhibitor at concentrations below and above the corresponding stoichiometry of inhibition. The mixtures (200 µL) and each component separately were analysed by size-exclusion chromatography on a Superdex 75 10/300 GL column (Cytiva) attached to an ÄKTA Pure FPLC system operated at a flow rate of 0.75 mL min^{-1} . The column was calibrated using the LMW and HMW Calibration Kits (Cytiva), and the protein elution profiles were recorded at λ = 280 nm. We collected 0.5 mL fractions and analysed 30 μ L aliquots by 10% SDS-PAGE (acrylamide/bis-acrylamide ratio = 33:1) using a Tris · HCl/Tricine buffer system.75

3.8 Kinetic studies of the inhibition of MMPs by PotA

MMPs were incubated with increasing concentrations of recombinant PotA up to a 1:5 enzyme:inhibitor molar ratio for 15 min at 30 °C in activity buffer, which was 50 mM Tris HCl, 10 mM calcium chloride, 150 mM sodium chloride, 0.05% Brij35, pH 7.5 for all MMPs except MMP-14 (50 mM Tris·HCl, 3 mM calcium chloride, 1 µM zinc chloride, pH 8.5). Residual enzymatic activity was measured as previously reported73 using the fluorogenic substrates Abz-R-P-L-A-L-W-R-S-Q-E-D-Dnp (for MMP-2, MMP-10, human and mouse MMP-12, and MMP-13), Abz-R-P-L-G-L-W-G-A-Q-E-D-Dnp (for MMPs 1, 7, 8, 9, 14 and 20) or Mca-R-P-K-P-V-E-Nva-W-R-K(Dnp)-NH2 (for MMP-3). MMPs were first titrated with the small-molecule active-site inhibitor GM6001 (R&D Systems Europe). K_i values were derived from non-linear inhibition curves as previously described.76 Data were plotted considering tight-binding inhibition,⁷⁷ and the associated K_i values were determined graphically (Table S2[†]).

3.9 Stability of potempins, isolated and in complex with target peptidases

Mixtures of karilysin, mirolase, mirolysin or subtilisin (10 µM) with PotA (12 μ M), PotC (15 μ M), PotD (15 μ M) or PotC (75 μ M), respectively, in 25 μ L assay buffer were incubated at 4, 20 or 37 ° C for 24 h before SDS-PAGE analysis and the determination of the residual proteolytic activity against Azocoll. Isolated peptidases or their complexes with inhibitors incubated for 15 min ("fresh complexes") served as controls for the activity of the free enzymes and the residual activity of the complexes, respectively. To assess susceptibility to proteolytic degradation and/or inactivation by non-target peptidases, potempins (10 µM) were incubated alone or with neutrophil elastase, trypsin, chymotrypsin, Kgp, RgpB or Tpr protease at a 1:100 enzyme:inhibitor molar ratio for 8 h at 37 °C in assay buffer. For cysteine peptidases (gingipains and Tpr), the assay buffers also contained 10 mM cysteine. After incubation, potempin integrity was determined by 10% SDS-PAGE and inhibitory activity was tested against the corresponding KLIKK-peptidases with Azocoll as the substrate.

3.10 Cultivation of T. forsythia

T. forsythia strain ATCC 43037 was grown at 37 °C in anaerobic chambers (Whitley A85 Workstation) on tryptic soy broth (30 g L^{-1}) with 5 g L^{-1} yeast extract supplemented with 0.5 mg L^{-1} haemin, 1 mg L⁻¹ menadione, and 10 mg L⁻¹ N⁻¹-acetylmuramic acid. Solid cultures were further supplemented with 5% sheep blood and solidified with 1.5% agar. For liquid cultures, we added 5% foetal bovine serum.

3.11 Cell fractionation, western blotting, and dot blot analysis

T. forsythia cultures and cells were fractioned as previously described for P. gingivalis78 except that inner membranes were solubilized with a solution containing 0.1% sarcosyl instead of 1% Triton X-100. Protein concentration was determined by the BCA assay (Sigma-Aldrich). Fractions resolved by 10% SDS-PAGE were electrotransferred onto polyvinylidene difluoride membranes (Bio-Rad, 0.22 µm pores) at 15 V for 40 min using a semi-dry transfer unit (Bio-Rad) and a transfer buffer comprising 50 mM Tris HCl, 40 mM glycine, 0.04% SDS and 10% methanol. The membranes were blocked with 5% (w/v) skimmed milk in 20 mM Tris·HCl, 0.5 M sodium chloride, 0.1% Tween-20, pH 7.5. Blots were probed with 1 μ g mL⁻¹ anti-PotA or anti-karilysin antibody, as well as through anti-BspA

rabbit serum (at 1:2000 dilution), in blocking solution, followed by incubation at room temperature for 1 h with a 1:20 000 dilution of a horseradish-peroxidase-conjugated goat antirabbit polyclonal secondary antibody in blocking solution. The signal was developed using the Pierce ECL western blotting substrate (Thermo Fisher Scientific). For dot-blot analysis, T. forsythia cells were harvested, washed and resuspended in cold phosphate-buffered saline. The OD₆₀₀ in suspensions of washed cells was adjusted to 1.0. To determine the cellular localisation of PotA by immunostaining, phosphate-buffered saline was supplemented with cOmplete EDTA-free protease inhibitor cocktail (Roche). Half of the intact cell suspensions were sonicated to disrupt the cells, and 5 µL of the intact or sonicated cell suspensions were spotted onto 0.22 µm nitrocellulose membranes (Bio-Rad), air-dried, and analysed as described above.

3.12 Mutagenesis of T. forsythia

Mutations were introduced into the T. forsythia genome by natural homologous recombination. A master plasmid (pKO-PINA-ermF), which introduces the antibiotic resistance cassette (ermF) before the potA-karilysin operon, was created from PCR-amplified inserts by the ligation of restrictiondigested DNA fragments into the pUC19 suicide vector. The ermF cassette was amplified from vector pURgpB-E (primers are listed in Table S1[†]). Flanking regions of the antibiotic resistance gene were amplified from T. forsythia sp. 43 037 genomic DNA. An upstream 664-base-pair fragment covered the region preceding the regulatory sequences of the potA-karilysin operon, and a downstream 1727-base-pair fragment spanned the proposed promoter region (502 base pairs), the whole potA coding DNA sequence, and a part of the karilysin coding DNA sequence. Next, vectors for complete potA deletion (pdelKO-PINA) and for the replacement of the N-terminal cysteine for lipid anchoring with alanine (pKO-PotA_C21A) were generated from the KO-PINA master plasmid in a single PCR step by Gibson assembly (https://www.neb.com/protocols/2012/12/11/ gibson-assembly-protocol-e5510) or SLIM mutagenesis. After verification by sequencing, the vectors were introduced into T. forsythia by electroporation, and recombinant clones were selected on medium supplemented with 5 μg mL⁻¹ erythromycin.26 Only the cysteine point mutant showed a complete lack of PotA protein without altered karilysin expression levels (Fig. 5C). This mutant was designated the potA^{null} strain.

3.13 In vivo fitness of T. forsythia

All animal studies took place in the Animal Facility of the Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland, in accordance with the protocols laid down by the Institutional Animal Care and Use II Regional Ethics Committee on Animal Experimentation, Kraków, Poland (approval no. 249/2019). Eight-week-old female C57BL/6 mice were obtained from Janvier Labs and housed in individually ventilated cages, with a 12 h photoperiod and a constant temperature of 22 \pm 1 °C. Animals were fed

a standard laboratory diet and water ad libitum under specific pathogen-free conditions. Mice were randomly assigned to experimental groups, and control and bacteria-infected mice were housed in separate cages. Mice were quarantined for at least 7 days prior to the experiment. Mid-dorsal subcutaneous implantation of surgical-grade titanium coil chambers (length 1.5 cm, diameter 5.0 \pm 0.08 mm) was carried out under anaesthesia with ketamine and xylazine (100 and 10 mg kg⁻¹, respectively). After 10 days, 1×10^8 colony-forming units of wild-type (WT) T. forsythia, karilysin-depleted T. forsythia (Δkly) or PotA-null T. forsythia (potA^{null}) in 100 µL sterile phosphatebuffered saline were injected into the chambers with a 27gauge syringe. Chamber exudates were harvested from mice at 0, 1, 2 and 24 h post-infection with the same syringe and 10-fold serial dilutions were prepared. All samples were plated on agar, and the plates were incubated anaerobically for 10 days at 37 °C. Visible colonies were counted to determine the total viable cell number.

3.14 Crystallization and diffraction data collection

Initial crystallization conditions were determined at the joint IBMB/IRB Automated Crystallography Platform (https:// www.ibmb.csic.es/en/platforms/automated-crystallographicplattform) using the sitting-drop vapour diffusion method to test up to \sim 1800 reservoir solutions, which were prepared by a Tecan robot in 96-well 2 mL DeepWell plates. Crystallization drops of 100 nL each of protein and reservoir solution were dispensed on Swissci 96-well 2-drop MRC crystallization plates (Molecular Dimensions) by a Phoenix nanodrop robot (Art Robbins) or a Cartesian Microsys 4000 XL robot (Genomic Solutions). Plates were stored in Bruker steady-temperature crystal farms at 20 or 4 °C. Best hits were scaled up whenever possible to drops containing 0.5, 1 or 2 µL of protein and reservoir solutions using Swissci 48-well MRC Maxi optimization plates (Molecular Dimensions). Crystals were cryoprotected by rapid passage through drops containing up to 25% (v/v) glycerol prior to vitrification in liquid nitrogen for transport to synchrotrons for data collection.

Isolated PotA (\sim 1.8 mg mL⁻¹ in 50 mM sodium chloride, 5 mM Tris HCl, pH 8.0) was crystallised using 20% [w/v] polyethylene glycol (PEG) 2000, 10 µM nickel chloride, 100 mM Tris·HCl, pH 8.5 as the reservoir solution. The PotA:karilysin complex (\sim 15 mg mL⁻¹ in 50 mM sodium chloride, 5 mM calcium chloride, 0.02% sodium azide, 5 mM Tris·HCl, pH 8.0) was crystallized using 25% PEG 6000, 100 mM MES, pH 6.0. The PotA:MMP-12 complex (\sim 8.5 mg mL⁻¹ in 2.5 mM calcium chloride, 150 mM sodium chloride, 20 mM Tris·HCl, pH 7.5) was crystallized using 30% PEG 3000, 200 mM sodium chloride, 100 mM Tris HCl, pH 7.0. The PotC:mirolase complex (~10 mg mL⁻¹ in 2 mM calcium chloride, 50 mM sodium chloride, 5 mM Tris HCl, pH 8.0) was crystallized using 19% PEG monomethyl ether 2000 in 100 mM mixed succinic acid, sodium dihydrogen phosphate and glycine at a molar ratio of 2:7:7 (pH 8.0). Isolated selenomethionine-derivatised PotD mutant I⁵³M $(\sim 14 \text{ mg L}^{-1} \text{ in 5 mM Tris} \cdot \text{HCl}, 50 \text{ mM sodium chloride}, 0.02\%$ sodium azide, pH 8.0) was crystallized using 20% PEG 3350,

0.2 M diammonium hydrogen citrate. Finally, native and selenomethionine-derivatised PotE (\sim 9 mg mL⁻¹ and \sim 10 mg mL⁻¹, respectively, in 50 mM sodium chloride, 5 mM Tris·HCl, pH 8.0) were crystallized using 20% PEG 8000, 100 mM HEPES, pH 7.5 and 20% PEG 1000, 100 mM Tris·HCl, pH 8.5, respectively.

Diffraction datasets were collected at 100 K on beam line ID23-1 of the ESRF synchrotron (Grenoble, France) or beam line XALOC of the ALBA synchrotron (Cerdanyola, Catalonia, Spain) on PILATUS 6M detectors (Dectris). Data were processed using *Xds*⁷⁹ and *Xscale*, and were transformed with *Xdsconv* to MTZ-format for the *Phenix*⁸⁰ and *Ccp4* (ref. 81) program packages. Table S3[†] provides statistical details for crystal parameters and data processing.

3.15 Structure solution, model building and refinement

The structure of the PotA:karilysin complex was solved first by likelihood-scored molecular replacement with *Phaser*.⁸² The coordinates of the protein part of the karilysin catalytic domain (Protein Data Bank access code (PDB) 4IN9^{38,83}) were used as a searching model to find the only molecule present in the asymmetric unit (a.u.) of the crystal. The phases derived from this solution were used for density modification and automatic model building with the *Arp/wArp* suite.⁸⁴ The structure of the PotA:MMP-12 complex was solved by molecular replacement with the coordinates of PotA from the PotA:karilysin complex and the protein part of the human MMP-12 catalytic domain (PDB 1JK3⁶²) to find the two complexes contained in the a.u. Finally, the structure of unbound PotA, with one protomer per a.u., was also solved by molecular replacement with the coordinates of PotA from the PotA:karilysin complex.

The structure of the PotC complex with mirolase was solved by molecular replacement with *Phaser*. A searching model to locate the only peptidase protomer in the a.u. was constructed based on the coordinates of the alkaline protease subtilisin BL from *Bacillus lentus* (PDB 1ST3⁸⁵), which is the closest relative by sequence similarity whose structure is available (as determined with *Blast*⁸⁶). The side chains were trimmed with *Chainsaw*⁸⁷ in *Ccp4* according to a sequence alignment with mirolase performed with *Multalin*.⁸⁸ Phases derived from the rotated and translated model were used for density modification and automatic model building as described above.

The structure of isolated selenomethionine-derivatized PotE, with two protomers in the a.u., was solved by single-wavelength anomalous diffraction by means of the *Autosol* procedure of the *Phenix* package⁸⁹ using data collected at the selenium absorption peak and processed with separate Friedel mates. These calculations found the four selenium atoms in the a.u. through the *Hyss* substructure search protocol⁹⁰ and produced phases with an estimated mean figure-of-merit of 0.29. Subsequently, *Autobuild* calculations within *Phenix*⁹¹ produced a Fourier map with phases with a mean figure-of-merit of 0.59 after density modification and twofold averaging. The structure of native PotE in a different space group with one protomer in the a.u. was solved by molecular replacement with the coordinates of selenomethionine-derivatised PotE.

Finally, the structure of the isolated selenomethioninederivatized PotD mutant I⁵³M, whose inhibitory ability was indistinguishable from WT PotD, was solved by molecular replacement with Phaser. Structure solution was hindered by the presence of six protomers in the a.u., an insufficient anomalous signal (six selenium atoms with partial occupancy per 79 kDa total molecular mass), and the presence of a strong peak (72% height of origin peak) at fractional coordinates 0.5, 0.5, 0.0, which resulted from translational non-crystallographic symmetry (NCS) and distorted the mean intensity distribution. At this point, a fragment encompassing \sim 50% of a model predicted by AlphaFold⁵⁸ served to find all the copies in the a.u. We selected parts of this model with values of the predicted localdistance difference test (pLLDT;ref. 92), which reliably estimates how well the prediction agrees with an experimental structure, scoring >85 (main chain and side chains) or >70 (main chain only). The correctness of the solution was verified by an anomalous Fourier map, which revealed a strong peak for the side chain of residue 53 of each protomer. The partial model solution and the structure factors (with separate Friedel mates) were then fed into Autosol, which found 10 heavy-atom positions and derived phases with an estimated mean figure-ofmerit of 0.88.

The Fourier maps after the structure-solution procedures were used for manual model building and completion with the *Coot* program,⁹³ alternating with crystallographic refinement using *Refine* in *Phenix*⁹⁴ and *Buster/Tnt*,⁹⁵ until the final models were obtained. Both procedures included non-crystallographic symmetry restraints where required and translation/libration/ screw-motion refinement. The final structures were validated with the *wwPDB Validation Service*. Table S3[†] provides statistics for the refinement and validation parameters, as well as the respective PDB access codes.

3.16 Comparative modelling and structure prediction

A high-confidence homology model of the forsilysin catalytic domain was computed with *Raptor-X*,⁹⁶ which uses the *Modeller* program.⁹⁷ The model was based on *Thermus thermophilus* thermolysin (PDB 4M65; $p = 2.38 \times 10^{-12}$; 29% sequence identity) and was validated using *Lomets*,⁹⁸ with a root-mean-square deviation of 0.9 Å.

For PotB1 and PotB2, models were predicted using *Alpha-Fold.*⁵⁸ The average pLLDT values were 90.8 and 91.1 for all atoms, respectively. These values exceed the high-accuracy cutoff of 90,⁹² and are thus classed as high confidence. Moreover, the structural similarity of PotB1 and PotB2 observed with PotE (Section 2.8) is unbiased because their structures were absent from the PDB sample on which *AlphaFold* was trained. This further underpins the high quality of the predictions for PotB1 and PotB2.

A homology model of the PotD:mirolysin complex was obtained by fitting protomer A of the PotD crystal structure into the active-site cleft of mirolysin based on the coordinates of the latter in complex with a C-terminal 14-residue cleavage product of PotD in the primed side of the cleft (PDB 6R7W⁴⁸), which had identified I¹⁰⁹–K¹¹⁰ as the reactive-site bond. The PotE:forsilysin complex was modelled based on the experimental coordinates of PotE, the comparative model of forsilysin, the complex between the standard-mechanism inhibitor IMPI and *B. thermoproteolyticus* thermolysin (PDB $3SSB^{40}$), and the knowledge of the forsilysin cleavage site in forsilysin (A¹¹⁵–I¹¹⁶; Section 2.2), which was identified as the reactive-site bond.

All computational models and predictions were visually inspected with *Coot*, manually corrected for clashes and chemical inconsistencies, regularised with *Coot* or the *Geometry_minimization* routine of *Phenix*, and validated with *Molprobity* (Table S4†). They can be downloaded as part of the ESI Materials[†].

3.17 Miscellaneous

Structural similarity was assessed using *Dali*⁹⁹ and *PDBeFold* at pdbe.org/fold based on program *Ssm*.¹⁰⁰ Structures were superimposed using *Ssm* in *Coot*, with *Fatcat*¹⁰¹ or with *Lsqkab*.¹⁰² Figures and coulombic surfaces were prepared using *Chimera*,¹⁰³ and protein interfaces were calculated using *Pisa*¹⁰⁴ at **https://www.ebi.ac.uk/pdbe/pisa**/. The interacting surface of a complex was defined as half the sum of the buried surface areas of either molecule. Phylogeny was assessed using *Multalin*⁸⁸ based on a sequence alignment using standard parameters. This alignment was also used to compute pairwise sequence identities, with and without signal peptides, with the *Sequence Manipulation Suite*.¹⁰⁵ Lipoprotein signal peptides were predicted using *LipoP v1.0*.¹⁰⁶

Data availability

The coordinates of the herein determined experimental structures are available from the Protein Data Bank (access codes in Table S3†). The homology models mentioned under Section 3.16 are retrievable from the ESI.† All herein developed biochemical reagents and tools, if not commercial, are available from the corresponding authors upon reasonable request.

Author contributions

J. P. and F. X. G.-R. conceived and supervised the project; M. K., I. W., M. M., A. S.-G., F. V. and T. M. produced and purified proteins, and performed functional studies *in vitro*; D. M. cloned the potempin genes, prepared mutants, and analysed operon structures and gene expression; M. B.-M. performed functional studies *in vivo*; I. B. T. and J. J. E. performed proteomics studies; A. C., T. Go., I. G.-F., M. L.-P., A. R.-B., J. L. A., I. d. D. and T. Gu. repurified and crystallized proteins; T. Go., A. R.-B. and U. E. collected diffraction data; J. P. analysed and interpreted biochemical and *in vivo* data; V. D. provided reagents; F. X. G.-R. solved and refined crystal structures, and obtained homology models; and J. P. and F. X. G.-R. wrote the manuscript with contributions from all authors.

Conflicts of interest

The authors declare no financial or non-financial conflicts of interest.

Acknowledgements

The authors thank Laura Company, Xandra Kreplin and Joan Pous from the joint IBMB/IRB Automated Crystallography Platform and the Protein Purification Service for assistance during purification, crystallization and SEC-MALLS experiments. The authors also thank the ESRF and ALBA synchrotrons for beamtime and the beamline staff for assistance during diffraction data collection and Dr Ashu Sharma (University of Buffalo, Buffalo, NY, USA) for providing rabbit antiserum against the BspA protein of T. forsythia. This study was supported in part by grants from Polish (National Science Centre and Ministry of Science and Higher Education), US (NIH/NIDR), Spanish, Danish and Catalan public and private bodies (grant/ fellowship references PID2019-107725RG-I00 and PDC2022-133344-I00 by MICIN/AEI/10.13039/501100011033, 2017SGR3, 2016/21/B/NZ1/00292, 1306/MOB/IV/2015/0, 2019/35/B/NZ1/ 03118, DE026280, Fundació "La Marató de TV3" 201815, and Novo Nordisk Foundation grant NNF18OC0032724). The authors thank Richard M. Twyman for editing the manuscript.

References

- P. I. Eke, B. A. Dye, L. Wei, G. D. Slade, G. O. Thornton-Evans, W. S. Borgnakke, G. W. Taylor, R. C. Page, J. D. Beck and R. J. Genco, *J. Periodontol.*, 2015, 86, 611–622.
- 2 G. Hajishengallis and T. Chavakis, *Nat. Rev. Immunol.*, 2021, 21, 426–440.
- 3 S. Listl, J. Galloway, P. A. Mossey and W. Marcenes, *J. Dent. Res.*, 2015, **94**, 1355–1361.
- 4 G. Hajishengallis, Nat. Rev. Immunol., 2015, 15, 30-44.
- 5 R. P. Darveau, Nat. Rev. Microbiol., 2010, 8, 481-490.
- 6 A. Endo, T. Watanabe, N. Ogata, T. Nozawa, C. Aikawa,
 S. Arakawa, F. Maruyama, Y. Izumi and I. Nakagawa, *ISME J.*, 2015, 9, 629–642.
- 7 R. Cortés-Vieyra, C. Rosales and E. Uribe-Querol, J. Immunol. Res., 2016, 2016, 1396106.
- 8 R. J. Lamont and G. Hajishengallis, *Trends Mol. Med.*, 2015, 21, 172–183.
- 9 J. Potempa, A. Banbula and J. Travis, *Periodontol*, 2000, 24, 153–192.
- I. de Diego, M. Ksiazek, D. Mizgalska, L. Koneru, P. Golik, B. Szmigielski, M. Nowak, Z. Nowakowska, B. Potempa, J. A. Houston, J. J. Enghild, I. B. Thøgersen, J. Gao, A. H. Kwan, J. Trewhella, G. Dubin, F. X. Gomis-Rüth, K. A. Nguyen and J. Potempa, *Sci. Rep.*, 2016, 6, 23123.
- 11 A. M. Lasica, M. Ksiazek, M. Madej and J. Potempa, *Front. Cell. Infect. Microbiol.*, 2017, 7, 215.
- D. Mizgalska, T. Goulas, A. Rodríguez-Banqueri, F. Veillard, M. Madej, E. Małecka, K. Szczesniak, M. Ksiazek, M. Widziołek, T. Guevara, U. Eckhard, M. Solà,

J. Potempa and F. X. Gomis-Rüth, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, e2103573118.

- 13 K. Sato, E. Sakai, P. D. Veith, M. Shoji, Y. Kikuchi, H. Yukitake, N. Ohara, M. Naito, K. Okamoto, E. C. Reynolds and K. Nakayama, *J. Biol. Chem.*, 2005, 280, 8668–8677.
- P. D. Veith, N. A. Nor Muhammad, S. G. Dashper, V. A. Likic,
 D. G. Gorasia, D. Chen, S. J. Byrne, D. V. Catmull and
 E. C. Reynolds, *J. Proteome Res.*, 2013, 12, 4449–4461.
- 15 Y. Narita, K. Sato, H. Yukitake, M. Shoji, D. Nakane, K. Nagano, F. Yoshimura, M. Naito and K. Nakayama, *Microbiology*, 2014, **160**, 2295–2303.
- 16 P. D. Veith, N. M. O'Brien-Simpson, Y. Tan, D. C. Djatmiko, S. G. Dashper and E. C. Reynolds, *J. Proteome Res.*, 2009, 8, 4279–4292.
- 17 N. D. Rawlings and A. Bateman, *Protein Sci.*, 2021, **30**, 83–92.
- 18 N. Cerdà-Costa and F. X. Gomis-Rüth, *Protein Sci.*, 2014, 23, 123–144.
- 19 H. B. Boldt, M. T. Overgaard, L. S. Laursen, K. Weyer, L. Sottrup-Jensen and C. Oxvig, *Biochem. J.*, 2001, 358, 359–367.
- 20 F. X. Gomis-Rüth, J. Biol. Chem., 2009, 284, 15353-15357.
- 21 C. Tallant, A. Marrero and F. X. Gomis-Rüth, *Biochim. Biophys. Acta, Mol. Cell Res.*, 2010, **1803**, 20–28.
- 22 L. Marino-Puertas, T. Goulas and F. X. Gomis-Rüth, *Biochim. Biophys. Acta, Mol. Cell Res.*, 2017, **1864**, 2026– 2035.
- 23 M. Ksiazek, D. Mizgalska, S. Eick, I. B. Thøgersen, J. J. Enghild and J. Potempa, *Front. Microbiol.*, 2015, 6, 312.
- 24 J. Koziel, A. Y. Karim, K. Przybyszewska, M. Ksiazek, M. Rapala-Kozik, K. A. Nguyen and J. Potempa, *J. Innate Immun.*, 2010, 2, 288–293.
- 25 M. Jusko, J. Potempa, A. Y. Karim, M. Ksiazek, K. Riesbeck, P. Garred, S. Eick and A. M. Blom, *J. Immunol.*, 2012, **188**, 2338–2349.
- 26 D. Bryzek, M. Ksiazek, E. Bielecka, A. Y. Karim, B. Potempa, D. Staniec, J. Koziel and J. Potempa, *Mol. Oral Microbiol.*, 2014, 29, 294–306.
- 27 M. Ksiazek, A. Y. Karim, D. Bryzek, J. J. Enghild,
 I. B. Thøgersen, J. Koziel and J. Potempa, *Biol. Chem.*, 2015, 396, 261–275.
- M. Jusko, J. Potempa, D. Mizgalska, E. Bielecka, M. Ksiazek,
 K. Riesbeck, P. Garred, S. Eick and A. M. Blom, *J. Immunol.*,
 2015, 195, 2231–2240.
- 29 L. Koneru, M. Ksiazek, I. Waligorska, A. Straczek, M. Lukasik, M. Madej, I. B. Thøgersen, J. J. Enghild and J. Potempa, *Biol. Chem.*, 2017, **398**, 395–409.
- 30 M. Eckert, D. Mizgalska, A. Sculean, J. Potempa, A. Stavropoulos and S. Eick, *Mol. Oral Microbiol.*, 2018, 33, 240–248.
- 31 A. Philips, I. Stolarek, L. Handschuh, K. Nowis, A. Juras, D. Trzcinski, W. Nowaczewska, A. Wrzesinska, J. Potempa and M. Figlerowicz, *BMC Genomics*, 2020, 21, 402.
- 32 T. Kantyka, N. D. Rawlings and J. Potempa, *Biochimie*, 2010, 92, 1644–1656.

- 33 G. Dubin, B. Wladyka, J. Stec-Niemczyk, D. Chmiel, M. Zdzalik, A. Dubin and J. Potempa, *Biol. Chem.*, 2007, 388, 227–235.
- 34 T. F. Kagawa, P. W. O'Toole and J. C. Cooney, Mol. Microbiol., 2005, 57, 650–666.
- 35 U. Baumann, M. Bauer, S. Letoffe, P. Delepelaire and C. Wandersman, J. Mol. Biol., 1995, 248, 653–661.
- 36 R. E. Feltzer, R. D. Gray, W. L. Dean and W. M. Pierce Jr, *J. Biol. Chem.*, 2000, **275**, 21002–21009.
- 37 H. Nagase, R. Visse and G. Murphy, *Cardiovasc. Res.*, 2006, 69, 562–573.
- 38 N. Cerdà-Costa, T. Guevara, A. Y. Karim, M. Ksiazek, K. A. Nguyen, J. L. Arolas, J. Potempa and F. X. Gomis-Rüth, *Mol. Microbiol.*, 2011, **79**, 119–132.
- 39 F. X. Gomis-Rüth, K. Maskos, M. Betz, A. Bergner, R. Huber,
 K. Suzuki, N. Yoshida, H. Nagase, K. Brew, G. P. Bourenkov,
 H. Bartunik and W. Bode, *Nature*, 1997, 389, 77–81.
- 40 J. L. Arolas, T. O. Botelho, A. Vilcinskas and F. X. Gomis-Rüth, *Angew. Chem., Int. Ed. Engl.*, 2011, **50**, 10357–10360.
- 41 G. B. Cole, T. J. Bateman and T. F. Moraes, *J. Biol. Chem.*, 2021, **296**, 100147.
- 42 C. L. Noland, M. D. Kattke, J. Diao, S. L. Gloor, H. Pantua, M. Reichelt, A. K. Katakam, D. Yan, J. Kang, I. Zilberleyb, M. Xu, S. B. Kapadia and J. M. Murray, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, E6044–E6053.
- 43 P. D. Veith, Y. Y. Chen, D. Chen, N. M. O'Brien-Simpson, J. D. Cecil, J. A. Holden, J. C. Lenzo and E. C. Reynolds, *J. Proteome Res.*, 2015, 14, 5355–5366.
- 44 S. I. Narita and H. Tokuda, *Biochim. Biophys. Acta, Mol. Cell Biol. Lipids*, 2017, **1862**, 1414–1423.
- 45 S.-W. Lee, M. Sabet, H.-S. Um, J. Yang, H. C. Kim and W. Zhu, *Gene*, 2006, **371**, 102–111.
- 46 S. R. Myneni, R. P. Settem, T. D. Connell, A. D. Keegan, S. L. Gaffen and A. Sharma, *J. Immunol.*, 2011, 187, 501–509.
- 47 A. Y. Karim, M. Kulczycka, T. Kantyka, G. Dubin, A. Jabaiah, P. S. Daugherty, I. B. Thogersen, J. J. Enghild, K. A. Nguyen and J. Potempa, *Biol. Chem.*, 2010, **391**, 105–117.
- 48 T. Guevara, A. Rodríguez-Banqueri, M. Ksiazek, J. Potempa and F. X. Gomis-Rüth, *IUCrJ*, 2020, 7, 18–29.
- 49 K. M. Zak, M. J. Bostock, I. Waligorska, I. B. Thøgersen, J. J. Enghild, G. M. Popowicz, P. Grudnik, J. Potempa and M. Ksiazek, *J. Enzyme Inhib. Med. Chem.*, 2021, 36, 1267– 1281.
- 50 M. Ksiazek, D. Mizgalska, J. J. Enghild, C. Scavenius, I. B. Thøgersen and J. Potempa, *J. Biol. Chem.*, 2015, **290**, 658–670.
- 51 T. Goulas, M. Ksiazek, I. Garcia-Ferrer, A. M. Sochaj-Gregorczyk, I. Waligorska, M. Wasylewski, J. Potempa and F. X. Gomis-Rüth, *J. Biol. Chem.*, 2017, **292**, 10883–10898.
- 52 A. Sochaj-Gregorczyk, M. Ksiazek, I. Waligorska,
 A. Straczek, M. Benedyk, D. Mizgalska, I. B. Thøgersen,
 J. J. Enghild and J. Potempa, *FASEB J.*, 2020, 34, 619–630.
- 53 A. M. Houghton, W. O. Hartzell, C. S. Robbins, F. X. Gomis-Rüth and S. D. Shapiro, *Nature*, 2009, **460**, 637–641.
- 54 M. Aristorena, E. Gallardo-Vara, M. Vicen, M. de Las Casas-Engel, L. Ojeda-Fernández, C. Nieto, F. J. Blanco, A. C. Valbuena-Díez, L. M. Botella, P. Nachtigal,

A. L. Corbi, M. Colmenares and C. Bernabeu, *Int. J. Mol. Sci.*, 2019, **20**, 3107.

- 55 V. Arcus, Curr. Opin. Struct. Biol., 2002, 12, 794-801.
- 56 D. B. Roche, P. D. Viet, A. Bakulina, L. Hirsh, S. C. E. Tosatto and A. V. Kajava, *J. Struct. Biol.*, 2018, **201**, 130–138.
- 57 K. Ozawa and M. Laskowski Jr, *J. Biol. Chem.*, 1966, 241, 3955-3961.
- 58 J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger, K. Tunyasuvunakool, R. Bates, A. Zidek, A. Potapenko, A. Bridgland, C. Meyer, S. A. A. Kohl, A. J. Ballard, A. Cowie, B. Romera-Paredes, S. Nikolov, R. Jain, J. Adler, T. Back, S. Petersen, D. Reiman, E. Clancy, M. Zielinski, M. Steinegger, M. Pacholska, T. Berghammer, S. Bodenstein, D. Silver, O. Vinyals, A. W. Senior, K. Kavukcuoglu, P. Kohli and D. Hassabis, *Nature*, 2021, 596, 583–589.
- 59 I. Schechter and A. Berger, *Biochem. Biophys. Res. Commun.*, 1967, **27**, 157–162.
- 60 F. X. Gomis-Rüth, T. O. Botelho and W. Bode, *Biochim. Biophys. Acta*, 2012, **1824**, 157–163.
- 61 A. Gimeno, R. Beltrán-Debón, M. Mulero, G. Pujadas and S. Garcia-Vallvé, *Drug Discovery Today*, 2020, 25, 38–57.
- 62 R. Lang, A. Kocourek, M. Braun, H. Tschesche, R. Huber,
 W. Bode and K. Maskos, *J. Mol. Biol.*, 2001, 312, 731–742.
- 63 A. Cuppari, H. Körschgen, D. Fahrenkamp, C. Schmitz, T. Guevara, K. Karmilin, M. Kuske, M. Olf, E. Dietzel, I. Yiallouros, D. de Sanctis, T. Goulas, R. Weiskirchen, W. Jahnen-Dechent, J. Floehr, W. Stoecker, L. Jovine and F. X. Gomis-Rüth, *IUCrJ*, 2019, 6, 317–330.
- 64 U. Eckhard, H. Körschgen, N. von Wiegen, W. Stöcker and F. X. Gomis-Rüth, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, e2023839118.
- 65 J. L. Arolas, T. Goulas, A. Cuppari and F. X. Gomis-Rüth, *Chem. Rev.*, 2018, **118**, 5581–5597.
- 66 M. Laskowski Jr and I. Kato, *Annu. Rev. Biochem.*, 1980, **49**, 593–626.
- 67 W. Bode and R. Huber, Eur. J. Biochem., 1992, 204, 433-451.
- 68 M. Laskowski Jr and M. A. Qasim, *Biochim. Biophys. Acta*, 2000, 1477, 324–337.
- 69 S. R. Mendes, U. Eckhard, A. Rodríguez-Banqueri, T. Guevara, P. Czermak, E. Marcos, A. Vilcinskas and F. X. Gomis-Rüth, *Comput. Struct. Biotechnol. J.*, 2022, 20, 534–544.
- 70 Y.-D. Li, Z.-Y. Xie, Y.-L. Du, Z. Zhou, X.-M. Mao, L.-X. Lv and Y.-Q. Li, *Gene*, 2009, **436**, 8–11.
- 71 C. Bodet, F. Chandad and D. Grenier, *Microbes Infect.*, 2006, **8**, 27–35.
- 72 H. Hasturk, A. Kantarci and T. E. van Dyke, *Front. Immunol.*, 2012, **3**, 118.
- 73 A. S. Lamort, R. Gravier, A. Laffitte, L. Juliano, M. L. Zani and T. Moreau, *Biol. Chem.*, 2016, **397**, 469–484.
- 74 C. Tallant, R. García-Castellanos, J. Seco, U. Baumann and F. X. Gomis-Rüth, *J. Biol. Chem.*, 2006, 281, 17920–17928.
- 75 H. Schägger and G. von Jagow, *Anal. Biochem.*, 1987, **166**, 368–379.
- 76 T. Moreau, N. Gutman, A. el Moujahed, F. Esnard and F. Gauthier, *Eur. J. Biochem.*, 1986, **159**, 341–346.

- 77 L. N. Easson and E. Stedman, *Proc. R. Soc. London, Ser. B*, 1936, **121**, 142–164.
- 78 A. M. Lasica, T. Goulas, D. Mizgalska, X. Zhou, I. de Diego, M. Ksiazek, M. Madej, Y. Guo, T. Guevara, M. Nowak, B. Potempa, A. Goel, M. Sztukowska, A. T. Prabhakar, M. Bzowska, M. Widziolek, I. B. Thøgersen, J. J. Enghild, M. Simonian, A. W. Kulczyk, K. A. Nguyen, J. Potempa and F. X. Gomis-Rüth, *Sci. Rep.*, 2016, 6, 37708.
- 79 W. Kabsch, Acta Crystallogr., Sect. D: Biol. Crystallogr., 2010, 66, 125–132.
- 80 P. D. Adams, P. V. Afonine, G. Bunkoczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger and P. H. Zwart, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2010, 66, 213–221.
- 81 M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. Keegan, E. B. Krissinel, A. G. Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin and K. S. Wilson, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2011, 67, 235–242.
- 82 A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni and R. J. Read, *J. Appl. Crystallogr.*, 2007, 40, 658–674.
- 83 T. Guevara, M. Ksiazek, P. D. Skottrup, N. Cerda-Costa, S. Trillo-Muyo, I. de Diego, E. Riise, J. Potempa and F. X. Gomis-Rüth, *Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun.*, 2013, 69, 472–476.
- 84 G. G. Langer, S. Hazledine, T. Wiegels, C. Carolan and V. S. Lamzin, Acta Crystallogr., Sect. D: Biol. Crystallogr., 2013, 69, 635–641.
- 85 D. W. Goddette, C. Paech, S. S. Yang, J. R. Mielenz, C. Bystroff, M. E. Wilke and R. J. Fletterick, *J. Mol. Biol.*, 1992, **228**, 580–595.
- 86 S. F. Altschul and E. V. Koonin, *Trends Biochem. Sci.*, 1998, 23, 444–447.
- 87 N. Stein, J. Appl. Crystallogr., 2008, 41, 641-643.
- 88 F. Corpet, Nucleic Acids Res., 1988, 16, 10881-10890.
- 89 T. C. Terwilliger, P. D. Adams, R. J. Read, A. J. McCoy, N. Moriarty, R. W. Grosse-Kunstleve, P. V. Afonine, P. H. Zwart and L. W. Hung, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2009, 65, 582–601.
- 90 R. W. Grosse-Kunstleve and P. D. Adams, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2003, **59**, 1966–1973.
- 91 T. C. Terwilliger, R. W. Grosse-Kunstleve, P. V. Afonine, N. W. Moriarty, P. H. Zwart, L. W. Hung, R. J. Read and P. D. Adams, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2008, 64, 61–69.
- 92 K. Tunyasuvunakool, J. Adler, Z. Wu, T. Green, M. Zielinski, A. Zidek, A. Bridgland, A. Cowie, C. Meyer, A. Laydon, S. Velankar, G. J. Kleywegt, A. Bateman, R. Evans, A. Pritzel, M. Figurnov, O. Ronneberger, R. Bates, S. A. A. Kohl, A. Potapenko, A. J. Ballard, B. Romera-Paredes, S. Nikolov, R. Jain, E. Clancy, D. Reiman, S. Petersen, A. W. Senior, K. Kavukcuoglu, E. Birney,

P. Kohli, J. Jumper and D. Hassabis, *Nature*, 2021, **596**, 590–596.

- 93 A. Casañal, B. Lohkamp and P. Emsley, *Protein Sci.*, 2020, 29, 1069–1078.
- 94 D. Liebschner, P. V. Afonine, M. L. Baker, G. Bunkóczi, V. B. Chen, T. I. Croll, B. Hintze, L.-W. Hung, S. Jain, A. J. McCoy, N. W. Moriarty, R. D. Oeffner, B. K. Poon, M. G. Prisant, R. J. Read, J. S. Richardson, D. C. Richardson, M. D. Sammito, O. V. Sobolev, D. H. Stockwell, T. C. Terwilliger, A. G. Urzhumtsev, L. L. Videau, C. J. Williams and P. D. Adams, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2019, 75, 861–877.
- 95 O. S. Smart, T. O. Womack, C. Flensburg, P. Keller, W. Paciorek, A. Sharff, C. Vonrhein and G. Bricogne, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2012, 68, 368–380.
- 96 M. Källberg, H. Wang, S. Wang, J. Peng, Z. Wang, H. Lu and J. Xu, *Nat. Protoc.*, 2012, 7, 1511–1522.
- 97 B. Webb and A. Šali, Methods Mol. Biol., 2017, 1654, 39-54.
- 98 W. Zheng, C. Zhang, Q. Wuyun, R. Pearce, Y. Li and Y. Zhang, *Nucleic Acids Res.*, 2019, 47, W429–W436.

- 99 L. Holm and P. Rosenström, *Nucleic Acids Res.*, 2010, 38, W545–W549.
- 100 E. Krissinel and K. Henrick, *Acta Crystallogr., Sect. D: Biol. Crystallogr.*, 2004, **60**, 2256–2268.
- 101 Z. Li, L. Jaroszewski, M. Iyer, M. Sedova and A. Godzik, *Nucleic Acids Res.*, 2020, **48**, W60–W64.
- 102 W. Kabsch, Acta Crystallogr., Sect. A: Cryst. Phys., Diffr., Theor. Gen. Crystallogr., 1976, 32, 922–923.
- 103 E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch,
 D. M. Greenblatt, E. C. Meng and T. E. Ferrin, *J. Comput. Chem.*, 2004, 25, 1605–1612.
- 104 E. Krissinel and K. Henrick, *J. Mol. Biol.*, 2007, **372**, 774–797.
- 105 P. Stothard, Biotechniques, 2000, 28, 1102–1104.
- 106 A. S. Juncker, H. Willenbrock, G. Von Heijne, S. Brunak, H. Nielsen and A. Krogh, *Protein Sci.*, 2003, 12, 1652–1662.
- 107 V. Friedrich, C. Gruber, I. Nimeth, S. Pabinger, G. Sekot,
 G. Posch, F. Altmann, P. Messner, O. Andrukhov and
 C. Schäffer, *Mol. Oral Microbiol.*, 2015, 30, 451–473.